 TRACON Pharmaceuticals NASDAQ:TCON Inc shared positive results from the Independent Data Monitoring Committee IDMC review of interim safety and efficacy data from its ongoing ENVASARC pivotal trial for envafolimab in soft tissue sarcoma, a rare type of cancer that begins in the tissues. The San Diego company, which utilizes a capital-efficient product development platform to develop its clinical-stage pipeline of cancer therapies, said that for the ongoing ENVASARC pivotal trial, the IDMC recommended continued accrual as planned in both cohort A of single agent envafolimab, and cohort B of envafolimab given with Yervoy ipilimumab. 